EP1388341A1 — Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
Assigned to Sanofi Aventis Deutschland GmbH · Expires 2004-02-11 · 22y expired
What this patent protects
The present invention relates to acylamino-substituted heteroaromatic compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 and R 5 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmaceutically active compounds which are useful…
USPTO Abstract
The present invention relates to acylamino-substituted heteroaromatic compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 and R 5 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmaceutically active compounds which are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. They upregulate the expression of the enzyme endothelial nitric oxide (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.